In the I-SPY2 breast cancer trial, functional tumor volume (FTV) derived from dynamic contrast-enhanced MRI is used as a longitudinal measure of response to adjust patient randomization and evaluate drug efficacy. I-SPY2 is introducing a treatment “escalation” option, giving patients the opportunity to re-direct to potentially more effective treatment based on early indication of inferior response by MRI. We retrospectively investigated the ability of FTV reduction to predict inferior outcome. Combined criteria using FTV reduction at 3 and 6 weeks of treatment showed high PPV and high sensitivity in early detection of non-responders.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords